XRA
2-[4-(furan-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
| Created: | 2010-09-24 |
| Last modified: | 2021-03-01 |
Find Related PDB Entry |
|---|
Find related ligands:Help |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 49 |
| Chiral Atom Count | 0 |
| Bond Count | 52 |
| Aromatic Bond Count | 16 |
Chemical Component Summary | |
|---|---|
| Name | 2-[4-(furan-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine |
| Synonyms | Prazosin |
| Systematic Name (OpenEye OEToolkits) | [4-(4-azanyl-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone |
| Formula | C19 H21 N5 O4 |
| Molecular Weight | 383.401 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 12.01 | O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)c4occc4 |
| SMILES | CACTVS | 3.370 | COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4occc4 |
| SMILES | OpenEye OEToolkits | 1.7.0 | COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)c4ccco4 |
| Canonical SMILES | CACTVS | 3.370 | COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4occc4 |
| Canonical SMILES | OpenEye OEToolkits | 1.7.0 | COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)c4ccco4 |
| InChI | InChI | 1.03 | InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22) |
| InChIKey | InChI | 1.03 | IENZQIKPVFGBNW-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB00457 |
|---|---|
| Name | Prazosin |
| Description | Prazosin, also known as _Minipress_, is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988 [L5828]. It belongs to the class of drugs known as alpha-1 antagonists [FDA label], [A176630]. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares [A176618, A176621, A176624]. |
| Synonyms |
|
| Indication | This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents [FDA label]. Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD)[A176630]. |
| Categories |
|
| ATC-Code |
|
| CAS number | 19216-56-9 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Alpha-1A adrenergic receptor | MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS... | unknown | antagonist |
| Alpha-1B adrenergic receptor | MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGL... | unknown | antagonist |
| Alpha-1D adrenergic receptor | MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGA... | unknown | antagonist |
| Potassium voltage-gated channel subfamily H member 2 | MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCE... | unknown | inhibitor |
| Alpha-2A adrenergic receptor | MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFG... | unknown | binder |
| View More | |||
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL2 |
| PubChem | 4893 |
| ChEMBL | CHEMBL2 |
| ChEBI | CHEBI:8364 |
| CCDC/CSD | YARTEQ |














